A phase 2 trial found that across 12 tumor types, 53% of patients given PD-1 blockade therapy experienced a durable response, and the subsequent next-generation sequencing (NGS) of 12,019 cancers found that >5% of adenocarcinomas derived from 11/12 tissues were MMR deficient [34]. This evidence concerns the gene PDCD1 and neoplasm.